LifeVantage leadership emphasized what it calls an “activation” approach, positioning its products as supporting the body’s natural processes rather than traditional supplementation. The company’s tagline, “take it to make it,” reflects that theme, executives said.The company said its products are packaged in a way that supports recurring sales, with about 70% of revenue coming from monthly subscriptions. In terms of geographic mix, LifeVantage said nearly 80% of revenue comes from North America, with about ...

LifeVantage Conference Call Summary Company Overview - **Company Name**: LifeVantage (NasdaqCM: LFVN) - **Market Capitalization**: Approximately $65 million - **Revenue**: Around $200 million - **Financial Status**: Profitable and debt-free with a strong cash position - **Industry Focus**: Nutrigenomics, health and wellness supplements [1][2] Core Business Model - **Distribution Channel**: Direct selling with consultants in about 20 countries - **Revenue Model**: Approximately 70% of revenue generated from monthly subscriptions - **Product Categories**: Focus on wellness and personal care, with a significant presence in North America [2][3][4] Geographic Revenue Distribution - **Revenue Sources**: - North America: ~80% - Asia: 18% - Europe: 3% - **Industry Size**: The health and wellness industry is valued at approximately $170 billion, indicating significant growth opportunities outside North America [4] Recent Acquisition - **Acquisition**: LoveBiome, completed in November, marks LifeVantage's first acquisition - **Integration Status**: Fully integrated with the LifeVantage compensation plan and consultant base [4][5][35] Product Portfolio - **Flagship Product**: Protandim Nrf2, clinically proven to reduce oxidative stress by 40% in 30 days - **Other Key Products**: - TrueScience Liquid Collagen: Increases collagen production by 100% - MindBody: Focused on GLP-1 and weight management, showing a 200% increase in GLP-1 production and an average weight loss of 11 pounds over 12 weeks [6][10][11] - P84 (from LoveBiome): Targets gut health and increases the production of 14 different peptides [11][12] Financial Performance - **Gross Margin**: Historically around 80% - **Adjusted EBITDA Margin**: Increased from 5.5% in FY 2023 to just below 10%, with a long-term target of 12% - **Revenue Growth**: 14% growth over fiscal 2024, with a focus on international expansion [18][19][25] Capital Allocation Strategy - **Investment Focus**: Prioritizing internal investments, including product development and compensation plan enhancements - **Dividend Program**: Initiated in 2022 with annual increases; current yield is approximately 3.9% - **Share Repurchase**: Recently authorized a $60 million share repurchase program, replacing a previous authorization [22][24][25] Market Position and Future Outlook - **Competitive Landscape**: Acknowledgment of increased competition in the GLP-1 market, with plans to adjust pricing and marketing strategies as needed - **Consultant and Customer Base**: Approximately 50,000 active consultants and 70,000 active customers, with a stable consultant base seen as crucial for long-term growth [30][40][41] - **CEO Succession**: Ongoing search for a successor as the current CEO plans to retire in April [42][43] Additional Insights - **Product Bundling**: Research indicates synergistic benefits from combining products, enhancing average revenue per account - **Digital Investments**: Transitioning to Shopify for e-commerce to improve consumer experience and consultant support [16][23] This summary encapsulates the key points discussed during the LifeVantage conference call, highlighting the company's strategic direction, financial health, and market opportunities.

Core Insights - LifeVantage Corporation, a health and wellness company, will participate in the Sidoti Small Cap Conference on March 18-19, 2026, with CEO Steve Fife and CFO Carl Aure presenting [1][2]. Company Overview - LifeVantage Corporation, listed on Nasdaq as LFVN, specializes in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3]. - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and various activation-supporting nutrients [3]. - Founded in 2003 and headquartered in Lehi, Utah, LifeVantage operates through independent consultants who sell products and provide business opportunities [3].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Battalion Oil Corporation (BATL) has seen a substantial increase of 134%, trading at $27.54 [3] - TMD Energy Limited (TMDE) is up 28%, currently priced at $3.96 [3] - Ouster, Inc. (OUST) has risen by 16%, trading at $23.60 [3] - Venture Global, Inc. (VG) also increased by 16%, now at $13.28 [3] - Euroholdings Ltd. (EHLD) is up 12%, trading at $8.09 [3] - Marine Petroleum Trust (MARPS) has increased by 12%, priced at $5.82 [3] - Top Ships Inc. (TOPS) is up 12%, currently at $5.47 [3] - Cheniere Energy, Inc. (LNG) has risen by 8%, trading at $270.50 [3] - Indonesia Energy Corporation Limited (INDO) is up 8%, priced at $7.31 [3] - LifeVantage Corporation (LFVN) has increased by 8%, currently at $4.90 [3] Premarket Losers - MongoDB, Inc. (MDB) has decreased by 27%, trading at $235.63 [4] - Surgery Partners, Inc. (SGRY) is down 23%, currently priced at $12.09 [4] - Life360, Inc. (LIF) has fallen by 19%, trading at $43.30 [4] - Harrow, Inc. (HROW) is down 16%, currently at $45.01 [4] - Cardio Diagnostics Holdings, Inc. (CDIO) has decreased by 13%, trading at $4.51 [4] - Credo Technology Group Holding Ltd (CRDO) is down 12%, priced at $99.90 [4] - Nuvation Bio Inc. (NUVB) has fallen by 11%, currently at $5.14 [4] - Limbach Holdings, Inc. (LMB) is down 10%, trading at $79.69 [4] - On Holding AG (ONON) has decreased by 10%, currently priced at $41.99 [4] - Ivanhoe Electric Inc. (IE) is down 10%, trading at $15.06 [4]

Core Viewpoint - Lifevantage (LFVN) reported quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.22 per share, representing a -31.82% earnings surprise [1] - The company also posted revenues of $48.93 million for the quarter, missing the Zacks Consensus Estimate by 10.62% and down from $67.76 million a year ago [2] Company Performance - Over the last four quarters, Lifevantage has surpassed consensus EPS estimates only once [2] - The stock has underperformed, losing about 13% since the beginning of the year compared to the S&P 500's gain of 1.1% [3] Future Outlook - The company's earnings outlook will be crucial for investors, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.34 on revenues of $61.69 million, and for the current fiscal year, it is $1.06 on revenues of $226.02 million [7] Industry Context - Lifevantage belongs to the Zacks Medical - Dental Supplies industry, which is currently in the top 40% of over 250 Zacks industries [8] - The performance of Lifevantage's stock may be influenced by the overall outlook for the industry [8]

Core Insights - The company faced challenges in Q2 2026, with significant revenue and earnings declines compared to the previous year, primarily due to increased competition in the GLP-1 market following the launch of the MINDBODY system [1][4][13] - Despite these challenges, the company is optimistic about long-term growth, particularly through the integration of the LoveBiome acquisition and the launch of new products [6][10][11] Financial Performance - Q2 2026 net revenue was $48.9 million, down 27.8% from $67.8 million in Q2 2025, but up 2.9% sequentially from Q1 2026 [13][14] - Sales of the MINDBODY GLP-1 system decreased by $16.2 million compared to the prior year, while the LoveBiome product line contributed $4.1 million in revenue [13][14] - Gross profit percentage for Q2 was 74%, down from 80.5% in the prior year, primarily due to a one-time inventory reserve related to MINDBODY [15][18] Market Dynamics - The competitive landscape for GLP-1 products has shifted, with pharmaceutical options becoming more accessible and affordable, impacting the sales of the MINDBODY system [5][6] - The company is recognizing a reserve against a portion of its GLP-1 inventory to respond to these changing dynamics [6][18] Product Development and Launches - The integration of LoveBiome has led to operational synergies and the launch of new products, including Axila X and Phytopower B, which are expected to drive engagement and diversify the product portfolio [7][8][10] - The company is also focusing on the HealthyEdge stack, which combines Protandim NRS-2 with P84, as a key enrollment product for consultants [9][40] Strategic Initiatives - The company is modernizing its technology infrastructure through a partnership with Shopify, aiming to enhance e-commerce capabilities and improve customer experience [9][46][47] - A new $60 million share repurchase program has been authorized, reflecting the company's commitment to returning capital to shareholders [11][20] Future Outlook - The company expects revenue for fiscal 2026 to be in the range of $185 million to $200 million, with adjusted EBITDA of $15 million to $19 million [20][21] - The anticipated growth is supported by the positive momentum from the LoveBiome integration and upcoming product launches [21][54]

Financial Data and Key Metrics Changes - For Q2 of fiscal 2026, net revenue was $48.9 million, down 27.8% from $67.8 million in Q2 of fiscal 2025, but up 2.9% sequentially from Q1 [14] - The decline was primarily driven by a $16.2 million decrease in sales of the MindBody GLP-1 System, partially offset by $4.1 million in revenue from the LoveBiome product line [14] - Gross profit percentage decreased to 74% from 80.5% in the prior year, reflecting a one-time inventory obsolescence allowance [15] - GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year [17] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System significantly declined due to increased competition from pharmaceutical options, which are now more accessible and affordable [5][6] - The LoveBiome acquisition contributed $4.1 million in revenue, with two new products launched that are expected to drive engagement and growth [8][9] Market Data and Key Metrics Changes - Revenue in the Americas decreased 32.6% to $38.5 million, while revenue in Asia-Pacific and Europe decreased 2.1% to $10.4 million [15] - The Americas decline was attributed to a 25.2% decrease in total active accounts, primarily from the customer base [15] Company Strategy and Development Direction - The company is focused on stabilizing the GLP-1 business and exploring cost reduction opportunities to maintain profitability [7] - Continued integration of LoveBiome is expected to enhance product diversification and market growth [8] - The company is optimistic about its comprehensive wellness ecosystem, which includes various health products [10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance did not meet expectations but remains confident in long-term growth potential [4] - The company anticipates revenue in the range of $185 million to $200 million for fiscal 2026, with adjusted EBITDA of $15 million to $19 million [19] Other Important Information - A new $60 million share repurchase program was announced, replacing the previous program [18] - A quarterly cash dividend of $0.045 per share was declared, to be paid on March 16, 2026 [19] Q&A Session Summary Question: About LoveBiome transaction costs - The $3.7 million cash at closing was the actual purchase price for LoveBiome, structured in two components: cash down payment and future earnout based on revenue targets [23] Question: Update on MindBody marketing plans - A 20% discount promotion was initiated, along with an "Activate90" event for holistic health discussions and a new app feature for tracking health activities [26][27][28] Question: Revenue split expectations for the second half of the year - Management expects stabilization in MindBody trends and anticipates Q4 will likely have a higher proportion of revenue compared to Q3 [51][53]

Financial Data and Key Metrics Changes - For Q2 of fiscal 2026, net revenue was $48.9 million, down 27.8% from $67.8 million in Q2 of fiscal 2025, but up 2.9% sequentially from Q1 [14] - The decline was primarily driven by a $16.2 million decrease in sales of the MindBody GLP-1 System, partially offset by $4.1 million in revenue from the LoveBiome product line [14] - Gross profit percentage decreased to 74% from 80.5% in the prior year, reflecting a one-time inventory obsolescence allowance [15] - GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year [17] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System significantly declined due to increased competition from pharmaceutical options, which have become more accessible and affordable [5][6] - The LoveBiome acquisition contributed $4.1 million in revenue, with two new products launched that are expected to drive engagement and growth [8][9] Market Data and Key Metrics Changes - Revenue in the Americas decreased 32.6% to $38.5 million, while Asia-Pacific and Europe revenue decreased 2.1% to $10.4 million [15] - The Americas decline was attributed to a 25.2% decrease in total active accounts, primarily from the customer base [15] Company Strategy and Development Direction - The company is focused on stabilizing the GLP-1 business and exploring cost reduction opportunities while remaining committed to the MindBody GLP-1 System [7] - The integration of LoveBiome is seen as a strategic move to diversify the product portfolio and enhance market growth [8][11] - The company is modernizing its technology infrastructure through a partnership with Shopify to improve e-commerce capabilities and customer experience [10][40] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance did not meet expectations but expressed optimism about long-term growth in the health and wellness ecosystem [4] - The company expects revenue for fiscal 2026 to be in the range of $185 million to $200 million, with adjusted EBITDA of $15 million to $19 million [19] - Management believes the competitive dynamics in the GLP-1 market can be navigated due to the unique value proposition of their natural solutions [47] Other Important Information - The company announced a new $60 million share repurchase program and a quarterly cash dividend of $0.045 per share [18][19] - The CEO announced plans for retirement in April 2026, with a succession plan in place to ensure leadership continuity [20] Q&A Session Summary Question: What was the cash transaction price for LoveBiome? - The cash transaction price for LoveBiome was $3.7 million, with future earnouts based on revenue targets [23] Question: What impacted the reduction in cash on the balance sheet? - The reduction was primarily due to the cash transaction for LoveBiome, timing of accrued payables, and stock-based compensation settlements [24] Question: What are the marketing plans for MindBody as the weight loss season approaches? - The company initiated a go-to-market strategy with a 20% discount and events to engage customers and consultants [26][27] Question: How did LoveBiome impact consultant and customer numbers? - LoveBiome contributed $4 million in product revenue, but specific consultant numbers were not disclosed [30] Question: What are the expectations for revenue in the second half of the year? - The company anticipates a stabilization in MindBody trends and expects Q4 to have a higher proportion of revenue compared to Q3 [51][53]

Financial Data and Key Metrics Changes - For Q2 fiscal 2026, the company reported net revenue of $48.9 million, down 27.8% from $67.8 million in Q2 fiscal 2025, but up 2.9% sequentially from Q1 [13] - The gross profit percentage decreased to 74% from 80.5% in the prior year, primarily due to a one-time inventory obsolescence allowance [15] - GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year [17] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System decreased by $16.2 million compared to the prior year, significantly impacting overall revenue [14] - The LoveBiome product line contributed $4.1 million in revenue following the acquisition [14] - The decline in total active accounts was 25.2% in the Americas and 6.5% in Asia-Pacific and Europe, reflecting a decrease in the active customer base [15] Market Data and Key Metrics Changes - Revenue in the Americas decreased 32.6% to $38.5 million, while revenue in Asia-Pacific and Europe decreased 2.1% to $10.4 million [15] - The company noted a slight revenue increase in Japan on a constant currency basis [15] Company Strategy and Development Direction - The company is focused on stabilizing the GLP-1 business and exploring cost reduction opportunities to maintain profitability [5] - The integration of LoveBiome is expected to drive product diversification and market growth, with new product launches planned [8] - The company is committed to enhancing e-commerce capabilities through a partnership with Shopify, aiming to improve customer experience and conversion rates [10][40] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance did not meet expectations but expressed optimism about long-term growth in the health and wellness ecosystem [4] - The company expects revenue for fiscal 2026 to be in the range of $185 million to $200 million, with adjusted EBITDA of $15 million to $19 million [19] - Management emphasized the importance of natural solutions in the GLP-1 market, believing there is still significant demand for their products [47] Other Important Information - The company announced a new $60 million share repurchase program and a quarterly cash dividend of $0.045 per share [18][19] - The CEO announced plans for retirement in April 2026, with a succession plan in place to ensure leadership continuity [20] Q&A Session Summary Question: What was the cash transaction price for LoveBiome? - The cash transaction price related to LoveBiome was $3.7 million, structured in two components: a cash down payment and a future earnout based on revenue targets [23] Question: What impacted the reduction in cash on the balance sheet? - The reduction was primarily due to the cash transaction for LoveBiome, timing of accrued payables, and cash utilized for stock-based compensation [24] Question: What are the marketing plans for MindBody entering the weight loss season? - The company initiated a go-to-market strategy with a 20% discount on MindBody products and introduced a new app feature for tracking calories and activities [26][28] Question: How did LoveBiome impact consultant and customer numbers? - LoveBiome contributed $4 million in product revenue, but specific numbers on active consultants were not disclosed [30] Question: What is the revenue outlook for the second half of the year? - Management anticipates stabilization in MindBody trends and expects Q4 to have a higher proportion of revenue compared to Q3 [52]

Revenue Performance - Revenue for the second quarter of fiscal 2026 was $48.9 million, a decrease of 27.8% compared to the same period in fiscal 2025[5] - Revenue in the Americas region decreased by 32.6%, while revenue in the Asia/Pacific & Europe region decreased by 2.1%[5] - Total revenue for the three months ended December 31, 2025, was $48,931, a decrease of 28% compared to $67,762 in the same period of 2024[28] - For the six months ended December 31, 2025, revenue totaled $96,493,000, down from $114,976,000 in 2024[39] Profitability - Gross profit for the second quarter was $36.2 million, representing 74.0% of revenue, down from 80.5% in the prior year[6] - Net income for the second quarter was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share a year ago[10] - Adjusted EBITDA for the second quarter was $3.9 million, down from $6.5 million in the same period last year[11] - Gross profit for the six months ended December 31, 2025, was $74,026, down 20% from $92,290 in 2024[28] - Net income for the three months ended December 31, 2025, was $276, significantly lower than $2,550 in the same period of 2024[28] - Non-GAAP Adjusted EBITDA for the three months ended December 31, 2025, was $3,880, down from $6,474 in 2024[35] - GAAP Gross profit for the three months ended December 31, 2025, was $36,209,000, compared to $54,567,000 in 2024, reflecting a gross profit percentage of 74.0%[39] - Non-GAAP Gross profit for the three months ended December 31, 2025, was $38,577,000, with a gross profit percentage of 78.8%[39] - GAAP Gross profit for the six months ended December 31, 2025, was $74,026,000, compared to $92,290,000 in 2024, with a gross profit percentage of 76.7%[39] - Non-GAAP Gross profit for the six months ended December 31, 2025, was $76,394,000, maintaining a gross profit percentage of 79.2%[39] - The gross profit percentage decreased from 80.5% in Q4 2024 to 74.0% in Q4 2025, indicating a shift in profitability[39] - The company continues to focus on improving its gross profit margins despite the decline in revenue[39] Cash Flow and Financial Position - The company generated $0.5 million of cash from operations during the first six months of fiscal 2026, compared to $8.6 million in the same period of fiscal 2025[12] - Total liabilities decreased to $28,182 as of December 31, 2025, from $37,317 as of June 30, 2025[26] - Cash and cash equivalents decreased to $10,181 as of December 31, 2025, from $20,201 as of June 30, 2025[26] - Total stockholders' equity was $32,987 as of December 31, 2025, down from $34,641 as of June 30, 2025[26] Shareholder Actions - The company announced a new $60 million share repurchase program, replacing the previous program entirely[13] - A cash dividend of $0.045 per common share was declared, payable on March 16, 2026[14] Customer and Consultant Metrics - Active Independent Consultants decreased by 9.6% year-over-year to 47,000 as of December 31, 2025, from 52,000 in 2024[32] - Active Customers dropped by 27.7% to 68,000 in December 2025, compared to 94,000 in December 2024[32] Future Outlook - Fiscal 2026 revenue guidance is projected to be between $185 million and $200 million, with adjusted EBITDA expected to be between $15 million and $19 million[15] - The company plans to launch several new products in the LoveBiome line and expand into new international markets[4]